Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KIF11 | P52732 | 6/20 | 0.36 |
| ▸ | PDE2A | O00408 | 3/20 | 0.35 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.34 |
| ▸ | SCN4A | P35499 | 1/20 | 0.34 |
| ▸ | DYRK1A | Q13627 | 1/20 | 0.34 |
| ▸ | CSNK1D | P48730 | 1/20 | 0.33 |
| ▸ | LDHA | P00338 | 1/20 | 0.33 |
| ▸ | LDHB | P07195 | 1/20 | 0.33 |
| ▸ | HRH4 | Q9H3N8 | 1/20 | 0.33 |
| ▸ | PPARA | Q07869 | 1/20 | 0.32 |
| ▸ | CA1 | P00915 | 1/20 | 0.32 |
| ▸ | CA2 | P00918 | 1/20 | 0.32 |
| ▸ | HTR2A | P28223 | 1/20 | 0.32 |
| ▸ | HTR2C | P28335 | 1/20 | 0.32 |
| ▸ | HTR2B | P41595 | 1/20 | 0.32 |
| ▸ | AKR1B1 | P15121 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1033112 | 0.86 | KIF11 (0.36) | KIF11PDE2AEPHX2SCN4ADYRK1A | |
| SCHEMBL1075156 | 0.81 | MEN1 (0.39) | KIF11EPHX2SCN4ADYRK1ACSNK1D | |
| SCHEMBL1035129 | 0.81 | PTGER1 (0.35) | KIF11PDE2AEPHX2SCN4ADYRK1A | |
| SCHEMBL12732588 | 0.79 | BCL2L1 (0.39) | LDHALDHBHTR2B | |
| SCHEMBL4654027 | 0.78 | MEN1 (0.39) | KIF11PDE2AEPHX2SCN4ADYRK1A | |
| SCHEMBL1033037 | 0.76 | NPY1R (0.36) | KIF11PDE2AEPHX2SCN4ADYRK1A | |
| SCHEMBL27808915 | 0.75 | KIF11 (0.36) | KIF11PDE2AEPHX2SCN4ADYRK1A | |
| SCHEMBL1034047 | 0.74 | KIF11 (0.36) | KIF11PDE2AEPHX2SCN4ADYRK1A | |
| SCHEMBL1033672 | 0.74 | NPY1R (0.35) | PDE2AEPHX2SCN4ADYRK1ACSNK1D | |
| SCHEMBL24742599 | 0.74 | DAO (0.32) | LDHALDHB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3424917-A1 | ACTIVATOR FOR PEROXISOME PROLIFERATOR-ACTIVATED RECEPTOR | Nippon Chemiphar Co., Ltd. (JP) | 2019-01-09 | — | — | EP | disclosed |
| EP-2277874-B1 | ACTIVATOR FOR PEROXISOME PROLIFERATOR-ACTIVATED RECEPTOR | NIPPON CHEMIPHAR CO (JP) | 2018-06-27 | — | — | EP | disclosed |
| US-8648208-B2 | Activating agent for peroxisome proliferator activated receptor | NIPPON CHEMIPHAR CO. LTD. (JP) | 2014-02-11 | — | — | US | disclosed |
| WO-2011020001-A9 | USE OF PPAR DELTA LIGANDS FOR THE TREATMENT OR PREVENTION OF INFLAMMATION OR ENERGY METABOLISM/PRODUCTION RELATED DISEASES | CERENIS THERAPEUTICS S.A. (FR) | 2011-05-26 | — | — | WO | disclosed |
| US-20110098480-A1 | ACTIVATING AGENT FOR PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR | NIPPON CHEMIPHAR CO. LTD. (JP) | 2011-04-28 | — | — | US | disclosed |
| US-20110092517-A1 | Use of PPAR Delta Ligands for the Treatment or Prevention of Inflammation or Energy Metabolism/Production Related Diseases | Cerenis Therapeutics S.A. & Nippon Chemiphar Co., Ltd. | 2011-04-21 | — | — | US | disclosed |
| WO-2011020001-A2 | USE OF PPAR DELTA LIGANDS FOR THE TREATMENT OR PREVENTION OF INFLAMMATION OR ENERGY METABOLISM/PRODUCTION RELATED DISEASES | CERENIS THERAPEUTICS S.A. (FR) | 2011-02-17 | — | — | WO | disclosed |
| EP-2277874-A1 | ACTIVATOR FOR PEROXISOME PROLIFERATOR-ACTIVATED RECEPTOR | Nippon Chemiphar Co., Ltd. (JP) | 2011-01-26 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110092517-A1 | Use of PPAR Delta Ligands for the Treatment or Prevention of Inflammation or Energy Metabolism/Production Related Diseases | PPARD, PPARG, PPARA | KIF11 3712/4885PDE2A 1331/4885EPHX2 4803/4885 |
| US-20110098480-A1 | ACTIVATING AGENT FOR PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR | PPARA, PPARG, PPARD | KIF11 3991/4885PDE2A 1843/4885EPHX2 3401/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.